---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-290473"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-06-30T20:05:15+00:00"
generated_at: "2026-06-30T20:06:32.525355+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptevo awarded $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling studies

## Summary
- Grant of $1,499,951 from Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling studies for APVO451, a trispecific antibody targeting nectin-4, CD40, and CD3 for solid tumors.
- Funding is non-dilutive and on a reimbursement basis; project period through June 2028, subject to milestones and matching contributions.
- APVO451 advancing toward development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027.
- Grant provides external validation of APVO451's trispecific design and supports Aptevo's solid tumor immunotherapy efforts.
- Aptevo retains IP ownership; grant includes customary terms including acknowledgment and commercialization commitments.

## SEC filing metadata
- accession: 0001193125-26-290473
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-06-30T20:05:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526290473/0001193125-26-290473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526290473/apvo-20260629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-290473
- JSON: https://secwatch.observer/filing/0001193125-26-290473.json
- Plain text: https://secwatch.observer/filing/0001193125-26-290473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.